<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002412</url>
  </required_header>
  <id_info>
    <org_study_id>292C</org_study_id>
    <secondary_id>MKC-305</secondary_id>
    <nct_id>NCT00002412</nct_id>
  </id_info>
  <brief_title>A Study of MKC-442 in Combination With Other Anti-HIV Drugs</brief_title>
  <official_title>A Randomized, Double-Blind Study of MKC-442 Combined With Stavudine, Didanosine, and Hydroxyurea in HIV-Infected Patients Who Are Protease Inhibitor Experienced and Non-Nucleoside Reverse Transcriptase Inhibitor Naive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Triangle Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give MKC-442 plus&#xD;
      stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive either MKC-442 or placebo, along with stavudine(d4T),&#xD;
      didanosine(ddI), and hydroxyurea. Patients will be treated and followed for 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emivirine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        - Based on medical history, medical condition, prior use of antiretroviral drugs, and&#xD;
        genotypic analysis of the predominant strain of HIV-1 isolated from the plasma,&#xD;
        administration of a combination of two or more available antiretroviral agents by&#xD;
        prescription may be given with MKC-442.&#xD;
&#xD;
        Patient must have:&#xD;
&#xD;
          -  HIV infection with HIV-1 RNA greater than or equal to 5,000 by Roche Amplicor method&#xD;
             within 30 days of entry.&#xD;
&#xD;
          -  A failed protease inhibitor-containing regimen.&#xD;
&#xD;
          -  Negative serum beta human chorionic gonadotropin test within 30 days of entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior nucleoside reverse transcriptase and protease inhibitors.&#xD;
&#xD;
          -  Cytotoxic chemotherapy more than 30 days prior to entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Malabsorption or severe chronic diarrhea within 30 days prior to entry, or inability&#xD;
             to consume adequate oral intake because of chronic nausea, emesis, or abdominal or&#xD;
             esophageal discomfort.&#xD;
&#xD;
          -  Inadequately controlled seizure disorder.&#xD;
&#xD;
          -  Known intolerance to stavudine, didanosine, and/or hydroxyurea.&#xD;
&#xD;
          -  Acute and clinically significant medical event within 30 days of screening.&#xD;
&#xD;
          -  Any clinical or laboratory abnormality greater than Grade 3 toxicity, with the&#xD;
             exception of laboratory values given.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        - Any experimental antiretroviral therapy or immunomodulators directed against HIV-1, e.g.,&#xD;
        IL-4, cyclosporine steroids at doses greater than 40 mg/day.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        - Non-nucleoside reverse transcriptase inhibitor therapy.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy within 30 days of entry except to a local lesion.&#xD;
&#xD;
          -  Transfusion of blood or blood products within 21 days of screening.&#xD;
&#xD;
          -  Cytotoxic therapy within 3 months of study entry.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Active substance abuse that may interfere with compliance or protocol evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr Robert Wallace</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Didanosine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Stavudine</keyword>
  <keyword>Hydroxyurea</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <keyword>MKC 442</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Emivirine</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

